Drug-induced lung injury in a child (a clinical case)
https://doi.org/10.22448/AMJ.2025.1.53-58
EDN: HNCEUZ
Abstract
This article describes the clinical features, diagnosis, treatment, and prevention of drug-induced lung injury resulting from iatrogenic exposure to medications.
Using a clinical case of a 6-year-old patient, pulmonary damage caused by anti-tuberculosis drugs – isoniazid, ethambutol, and rifampicin – is analyzed. This case highlights the necessity for timely diagnosis and preventive strategies to avoid the development of interstitial lung disease in pediatric patients.
About the Authors
V. V. Shamraeva
Amur State Medical Academy Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Victoria V. Shamraeva
Blagoveshchensk
T. A. Solovyova
Amur Regional Children's Clinical Hospital
Russian Federation
Russian Federation
Tatyana A. Solovyova
Blagoveshchensk
E. I. Piskun
Amur Regional Children's Clinical Hospital
Russian Federation
Russian Federation
Elena I. Piskun
Blagoveshchensk
References
1. Kosarev V.V., Babanov S.A. Drug-induced lung impairment. Difficult Рatient. 2013; 11 (2–3): 34–41.
2. Trofimenko I.N. Chernyak B.A. Drug-induced interstitial lung lesions. Medical Council. 2016; 5: 52–59. DOI: https://doi.org/10.21518/2079-701X-2016-05-52-59 (In Russ.)
3. Camus P., Bonniaud P. Drug-induced respiratory disease. In: Palange P., Simonds A.K., editors. ERS handbook Respiratory Medicine 2nd edition. European Respiratory Society: Charlesworth Press, 2013. Р. 399–410.
4. Postnikov S.C., Gratsianskaya A.N., Kostyileva M.N. Drug pathology of the lungs. Pediatria n.a. G.N. Speransky. 2013; 92 (3): 130–135.
5. Schwaiblmair M., Behr W., Haeckel T., et al. Drug Induced Interstitial Lung Disease. Open Respiratory Medicine Journal. 2012; 6: 63–74. DOI: https://doi.org/10.2174/1874306401206010063
6. Cheltsov V.V., Martynov A.I. Medicinal lung damage. Clinical Pharmacology and Therapy. 2013; 2: 58–62. (In Russ.)
7. Prasad R., Gupta P., Singh A., Goel N. Drug induced pulmonary parenchymal disease. Drug Discoveries & Therapeutics. 2014; 8 (6): 232–237. DOI: https://doi.org/10.5582/ddt.2014.01046
8. Anaev E.K. Drug-induced interstitial lung disease: approaches to diagnostics and treatment. Therapeutic Archive. 2020; 92 (3): 84–91. DOI: https://doi.org/10.26442/00403660.2020.03.000399
9. Orlovа N.V., Ostroumovа O.D., Shikh E.V., et al. Lung Injury Induced by Antitumor Drugs: Diagnosis, Features of the Clinical Course, Risk Factors, Differential Diagnosis, Treatment, and Prevention. Part 1. Tuberculosis and Lung Diseases. 2021; 99 (7): 55–62. DOI: https://doi.org/10.21292/2075-1230-2021-99-7-55-62
10. Orlova N.V., Ostroumova O.D., Shikh E.V., et al. Lung Injury Induced by Antitumor Drugs: Prevalence, Certain Drugs and Their Mechanisms of Action. Part 2. Tuberculosis and Lung Diseases. 2021; 99 (8): 54–60. DOI: https://doi.org/10.21292/2075-1230-2021-99-8-54-60
11. Postnikov S.S., Polyaev Yu.A., Mylnikov A.A., et al. Intersticial pneumonitis, caused by pegylated interferon alfa-2a in a 4 months child with gigantic kaposi's haemangioepitheliom and kasabach – merrit phenomenon: a case report. Safety and Risk of Pharmacotherapy. 2014; 1: 23–26.
12. Erdal M.A., Alboğa D., Sunman B., et al. Nintedanib Treatment in a Child with Pulmonary Fibrosis. Turkish Journal of Pediatric Disease. 2024; 18 (1): 71–74. DOI: https://doi.org/10.12956/tchd.1324744.
Review
For citations:
Shamraeva V.V., Solovyova T.A., Piskun E.I. Drug-induced lung injury in a child (a clinical case). Amur Medical Journal. 2025;13(1):53-58. (In Russ.) https://doi.org/10.22448/AMJ.2025.1.53-58. EDN: HNCEUZ
Views:
7
JATS XML
Email this article 